| Similar Articles |
|---|
 |
Pharmaceutical Executive
June 1, 2011 |
To Screen or Not to Screen? What do our genetics tell us about our predisposition to certain diseases? What does this mean for pharmaceutical companies?   |
Bio-IT World
April 2006
Kevin Davies |
NitroMed Ties Gene Biomarkers to BiDil Benefit The FDA approval of BiDil, NitroMed's heart failure drug for blacks, raised howls of controversy. Now at a meeting of the American College of Cardiology, researchers presented two papers that offer the first preliminary hints of genetic factors that affect BiDil response. |
The Motley Fool
May 25, 2005
Karl Thiel |
A Gold Mine in Generics Will NitroMed's new math add up to investment success? |
The Motley Fool
June 16, 2005
Karl Thiel |
BiDil's Bid for a Narrow Label Although things appear to be going NitroMed's way, there is a dark horse spoiler looming in the shadows that should keep investors on their toes today. The company is seeking FDA approval for African-Americans only, but what if BiDil is given a broader label acceptance? |
Pharmaceutical Executive
November 1, 2011
Elizabeth O. Coulton |
Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients. |
BusinessWeek
June 27, 2005
Amy Barrett |
Color-Blind Drug Research Is Myopic Researchers will sometimes have to use the blunt instrument of race to help match patients with the right drugs. |
The Motley Fool
August 2, 2004
W.D. Crotty |
NitroMed: The New Taser? A new cardiac drug springs this stock into an eye-opening run. |
Pharmaceutical Executive
May 1, 2006 |
Marketing to Professionals: Ensuring Equality An interview with the National Medical Association president and medical director of the Northwest Indiana Dialysis Center on the racial issues surrounding enrollment of seniors in Medicare Part D, targeted advertising and promotion, and participation of minorities in clinical trials. |
